QUOTIENT SCIENCES LIMITED sell "Drug Substance"

This streamlined drug-substance development approach has cut manufacturing costs by 50% from preclinical through Phase I, backed by significant investment in technology and equipment to meet rising demand for complex small-scale manufacturing. Drawing on more than 40 years of synthetic organic chemistry experience alongside expertise in flow chemistry, synthetic biology and biocatalysis, the team optimizes manufacturing processes to save months of development time, offering process research and development plus solid-state services such as salt selection, polymorph screening, amorphous dispersions, crystallization development, and solid-state characterization (XRPD, DSC/TGA thermal analysis, DVS hygroscopy and hot-stage microscopy).